Register for our free email digests:
Cellegy Canada Inc.
Division of Adamis Pharmaceuticals Corp.
Latest From Human Genome Sciences Inc.
GlaxoSmithKline is working to establish an immuno-inflammation portfolio and extend learnings to other therapy areas. Sirukumab could be GSK's first new product in I&I beyond Benlysta. Chief Immunology Officer Paul-Peter Tak outlined his strategy in an interview with Scrip.
Merck rejected FDA's recommended endpoint to show efficacy in preventing C. difficile recurrence, which could make it difficult to gain approval for the product, headed to June 9 advisory panel review.
Company readies regulatory filings for bezlotoxumab as a monotherapy in preventing C. difficile, following presentation of positive MODIFY I and II data at the ICAAC meeting in San Diego.
The European Medicine Agency's scientific advisors group recommended on 22 May that Imbruvica (ibrutinib) should be indicated for the treatment of Waldenstr?m’s macroglobulinaemia (WM), a very rare blood cell cancer characterized by vast overproduction of immunoglobulin M (IgM). The recent approval of ibrutinib in the US, and its imminent approval in Europe not only provide WM patients with first- and second-line treatment options, but also, says one key opinion leader in WM, will provide a focus for more productively organized patient group and physician activity.
- Therapeutic Areas
- Vaxis Therapeutics Corp.
- North America
- Parent & Subsidiaries
- Adamis Pharmaceuticals Corp.
- Senior Management
James M Rae, CEO
C. B Ackman, Pres.
Michael A Adams, PhD, VP, Research
James D Banting, PhD, VP, Bus. Dev.
Jeremy P Heaton, MD, VP, Clinical Affairs
Bruce Ackman, Pres.
- Contact Info
Cellegy Canada Inc.
Phone: (613) 545-9461
116 Barrie St. Biosciences Complex
Kingston, K7L 3N6
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.